Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

Cunfu Li1 Department of General Surgery, Weihai Central Hospital, Weihai

Aizhai Xiang2 Department of Breast Surgery, Hangzhou First People’s Hospital, Nanjing Medical University, Hangzhou

Xianzhi Chen3 Department of General Surgery, Huainan First People’s Hospital, Huainan

Kai Yin4 Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Jinsong Lu4 Department of Breast Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University

Wenjin Yin5 Department of Breast Surgery, Fudan University Shanghai Cancer Center;6 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of ChinaCorrespondence[email protected]

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

Articles from other publishers (4)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials

Citations (4)

Articles from other publishers (4)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date